Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 462 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Abramson Cancer Center at Penn Medicine Clear all
Completed Not applicable Interventional

Breast Cancer Outreach Among Primary Care Patients

NCT05089903
View directory record Official record
Conditions
Breast Cancer
Interventions
Bulk Order, Texting, Clinician Endorsement, No Bulk Order, Standard Endorsement
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
24,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 1 Interventional Results available

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

NCT02434354
View directory record Official record
Conditions
Malignant Melanoma
Interventions
pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 14, 2026, 1:30 AM EDT
Completed No phase listed Observational

Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study

NCT01212731
View directory record Official record
Conditions
Malignancy, Glioma, Radiotherapy
Interventions
Photon treatment plans, Proton Treatment Plans, Neurocognitive evaluation, Advanced MRI imaging
Radiation · Behavioral · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 1 Interventional

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT01017133
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography
Radiation · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

Virtual Reality to Promote Relaxation Prior to Simulation

NCT06318338
View directory record Official record
Conditions
Cancer
Interventions
Virtual Reality Program
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

NCT01486784
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Birinapant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients

NCT06604247
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Cognitive Behavioral therapy for insomnia (CBT-I)
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 1:30 AM EDT
Withdrawn Phase 2 Interventional

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

NCT04134468
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Pegvorhyaluronidase alfa, Abraxane, Gemcitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

NCT03729518
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
Interventions
Radiation Therapy (IMRT or IMPT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Recruiting Phase 2 Interventional

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

NCT06747845
View directory record Official record
Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
Niraparib, FOLFIRI, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Staying Healthy With Follow-up Care: A Mobile Chatbot Feasibility Study for AYA Cancer Survivors

NCT05863702
View directory record Official record
Conditions
Survivorship
Interventions
Penny
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Early Phase 1 Interventional

Autophagy Induction After Bortezomib for Myeloma

NCT01594242
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

Project PLUS Lung Cancer Screening Promotion

NCT05937399
View directory record Official record
Conditions
Lung Cancer
Interventions
Intervention video, Control video
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

Functional MRI Use in Prostate Radiation Treatment Planning

NCT01985932
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 14, 2026, 1:30 AM EDT
Active, not recruiting Not applicable Interventional

Project Looking-Glass Evaluation

NCT06056063
View directory record Official record
Conditions
Cone-Beam Computed Tomography
Interventions
Halcyon 4.0
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

NCT04735068
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
Interventions
Binimetinib Pill, Hydroxychloroquine Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Communication Strategies to Increase HPV Vaccinations

NCT06784960
View directory record Official record
Conditions
Papilloma Viral Infection, Vaccine Hesitancy, Communication
Interventions
HPV Message 1, HPV Message 2, HPV Message 3, Control Message, Provider Strong-Recommendation Toolkit
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
9,002 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Recruiting No phase listed Observational

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

NCT03680677
View directory record Official record
Conditions
Leukemia, Acute, MDS
Interventions
Bone Marrow or Peripheral Blood Graft (BMT), Cancer-directed Therapy or Best Supportive Care, Frailty Assessment
Procedure · Other · Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional

Buddy Relationships in DermatoloGic Excisions for Skin Cancer

NCT04036344
View directory record Official record
Conditions
Skin Cancer Face, Quality of Life, Surgical Wound, Peer Mentorship
Interventions
Peer Mentorship Program
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Terminated Phase 1Phase 2 Interventional

Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

NCT00776373
View directory record Official record
Conditions
ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
Interventions
Rapamycin, High dose etoposide and cytarabine (HiVAC)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 14, 2026, 1:30 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas

NCT01985958
View directory record Official record
Conditions
Histological or Cytological Diagnosis of Pancreatic Carcinoma
Interventions
Radiation therapy
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 14, 2026, 1:30 AM EDT
Recruiting Not applicable Interventional

Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)

NCT06770855
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Total consolidative MPDT
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 1:30 AM EDT